A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, dose increasing study to evaluate the safety,
tolerability, pharmacokinetic(PK) profile, and antitumor efficacy of KL340399 intratumoral in
patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.